Interius BioTherapeutics just raised $76 million in seed funding to advance their clinical testing. Interius is a Philadelphia-based preclinical stage biotechnology company initially focused on treating hematologic malignancies by leveraging its novel gene delivery platform to generate CAR T cells directly in vivo. Founded by Saar Gill, a lead physician-scientist at the University of Pennsylvania’s Center for Cellular Immunotherapies.
